CLINUVEL announced that it will start treatment of vitiligo patients with its drug afamelanotide under a new study protocol (CUV104). The Company has received positive review from the Institutional Review Board (IRB) to commence the CUV104 study, which will be conducted at a North-American vitiligo expert centre. Up to six adult vitiligo patients with darker skin complexions (Fitzpatrick Skin Types IV-VI) will be enrolled in the CUV104 study, evaluating patients' response to afamelanotide as a monotherapy over six months.